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Abstract 
Influenza viruses are a group of pathogens in the family Orthomyoviridae, which are classified into 6 
genera (A,B,C, Thogotovirus, Isavirus and new unnamed genus). Type A influenza viruses are catego-
rized based on their surface glycoproteins: hemagglutinin (HA) and neuraminidase (NA). So far 17 HA 
and 9 NA subtypes have been identified. Influenza genome comprises of eight single-stranded nega-
tive-sense RNA segments that encode ten to twelve proteins (HA, NA, NP M1/M2, NS1/NS2, PA, PB1 
and PB2). Influenza replication cycle depends on the surface proteins binding to host cell receptors, pH 
mediated fusion and cell-mediated transcription and replication of the viral genome. Virus particles 
leave the host cell via budding. 
Influenza viruses cause global epidemic infections each year, the peak is from December to March. 
These pathogens have also contributed to six global pandemics identified so far. The latest pandemic 
outbreak was announced by WHO in 2009 which caused over 5000 hospitalizations in Finland. Factors 
contributing to the severity of clinical outcome can be either genetic, environmental or caused by hu-
man host features.  
This study aims to identify the susceptibility factors for severe influenza A infections and describe the 
phylodynamics of the latest pandemic A(H1N1)pdm09 from Finnish patient nasopharyngeal aspirates 
collected between 2009-2013. 
One-step reverse-transcription PCR was used to amplify all of the 8 segments equally. Fast and precise 
next-generation sequencing with Illumina 2000 sequencer was used to generate the sequences. Results 
were bioinformatically analysed using Bayesian modelling with Markov Chain Monte Carlo algorithms 
of probability distributions. Models analysed showed highest mutation rate in hemagglutinin protein. 
Phylodynamic analysis revealed higher mutation rate of HA and NA compared to other proteins.  
Subgroup specific polymorphisms (either in severe or mild cases) were not identified. In total 4657 
amino acid substitutions were located in 135 pandemic A(H1N1)pdm09 patient isolates and 238 in 10 
seasonal patient samples. Viral HA, NA and PB2 were more frequently mutated than other proteins. 
Interestingly this study identified double-resistant markers (E119K and S31N) to two antiviral drugs 
(amantadine and oseltamivir) in one patient isolate (A/Helsinki/598/2013). Previously reported D222 
polymorphism (without the signalling peptide) causing more severe clinical outcome was not identified 
in any of the patient isolates in this study.  
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Abbreviations 
 
ACT Auto-correction time 
ARDS Acute Respiratory Disease Syndrome 
CaMK2B Calcium/calmodulin kinase II beta 
cRNA Complementary RNA 
COPI Coat Protein Complex I 
CPSF Cleavage and polyadenylation specificity factor 
ECDC European Centre of Disease Prevention and Control 
eIF4A,E,G Eukaryotic initiation factor 4A,E,G 
ESS Effective sample size 
FDA Food and Drug Administration 
FGFR Fibroblast Growth Factor Receptor 
FIMM Institute for Molecular Medicine Finland 
GSK3 Glycogen synthase kinase 3 
HA Hemagglutinin 
HPD Highest posterior density 
HUSLAB Helsingin ja Uudenmaan sairaanhoitopiirin laboratoriokeskus 
ICU Intensive care unit 
M1 Matrix protein 1 
M2 Matrix protein 2 
MCMC Markoc Chain Monte Carlo 
NA Neuraminidase 
NAI Neuraminidase inhibitor 
NP Nucleocapsid protein 
NPA Nasopharyngeal aspirate 
NPC Nuclear pore complex 
NS1 Nonstructural protein 1 
NS2 Nonstructural protein 2 
PA Polymerase activity protein 
PABPII Poly(A) binding protein II 
PB1 Polymerase binding protein 1 
PB2 Polymerase binding protein 2 
PI3K Phosphaditylinositol-3-kinase 
PKR Protein kinase R  
RIG-I Retinoic-acid inducible gene I 
RT-PCR Reverse transcription polymerase chain reaction 
siRNA Short interfering RNA 
THL Terveyden ja hyvinvoinnin laitos (National Institute for Health and Welfare) 
TLR Toll-like receptor 
VLP Virus-like particles 
vATPase Vacuolar –type H+ - ATPase 
vRNA Viral RNA 
vRNP viral ribonucleoproteins
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This Master’s thesis is based on the following publications: 
1. Lakspere T., Tynell J. et al. Full-genome sequences of influenza A(H1N1)pdm09 
viruses isolated from Finnish patients during 2009-2013, Genome Annoucements, 
2013 (submitted) 
2. Lakspere T., Tynell J. et al. Genetic evolution of influenza A(H1N1)pdm09 virus (in 
preparation) 
Review of the literature 
Influenza virus 
Influenza viruses are globally distributed pathogens in the family Orthomyxoviridae (name 
derives from their ability to bind sialic acid in mucoproteins). They are classified into six 
genera (influenza virus A, B and C and three other genera). Influenza type A and B cause 
annual epidemics while type C viruses are milder and not so prevalent. Three distinct genera 
are tickborne mammalian viruses (Thogotovirus), Atlantic salmon infecting genus (Isavirus) 
and recently discovered arboviral viruses (members include Quarantil, Johnston Atoll and 
Lake Chad viruses). Hosts of different genera include birds, various mammals and humans 
(Lambert, Fauci 2010). First isolates of influenza viruses in humans were collected in 1933 (Smith, 
Andrewes et al. 1933).  
Type A influenza viruses are categorized based on sequences of two surface glycoproteins 
hemaglutinin (HA) and neuraminidase (NA). Up to this date 17 different HA (H1 to H17) 
and 9 NA subtypes (N1 to N9) have been identified (Lamb 2008, Briedis 2011). The World 
Health Organization (WHO) estimates the global disease burden to be up to 1 billion human 
infections, 3-5 million hospital cases and approximately 300 000-500 000 annual deaths 
(Girard, Cherian et al. 2005). 
The outcome of influenza infection is a combination with viral, host and environmental 
factors resulting the infection to be either asymptomatic, mild, severe or lethal. 
 
Structure of influenza viruses 
Influenza virions are quasi-spherical or filamentous particles. The latter are responsible for cell-
to-cell viral transmission while quasispherical virions may be part of human-to-human transmission of 
the virus. Diameter of the virus ranges between 80-120 nm. The viral particle consists of helical 
ribonucleoprotein complexes with viral membrane derived from host cell plasma membrane 
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(Briedis 2011). 
 
Influenza genome (total size 10-15 kbp varying in different genera) consists of eight distinct 
linear single-stranded negative sense RNA segments (from 890 to 2341 nucleotides long). 
Segments encode viral proteins: PB2, PB1-F1, PB1-F2, PA and PA-X (polymerase subunits), 
trimeric HA (hemagglutinin), NP (nucleoprotein), tetrameric NA (neuraminidase, also called 
sialidases), M1/M2 (matrix proteins) and dimeric NS1/ dimeric NS2 (non-structural proteins). 
Details of segments and encoded proteins are found in table 1. In addition, there has been 
studies on the identification of new influenza proteins like PA-N155, PA-182 which are N-
terminally truncated forms of PA affecting the replication events in influenza infection 
(Muramoto, Noda et al. 2013). 
Gene 
segment 
Length 
(nucleotide) 
Translated 
protein 
Protein 
size 
Function 
1 2316 PB2 759 Regulation of transcription 
2 2317 PB1 757 Polymerase activity, cleaving 
of pre-mRNAs 
PB1-F2 87-90 Enhancing immune cell 
apoptosis, localized in 
mitochondria 
3 2192 PA 716 Regulation of transcription 
and replication processes 
PA-X 252 Function in modulating host 
response to infection 
4 1752 HA 56 Major surface glycoprotein; 
sialic acid-receptor binding; 
antigenic determinant 
5 1541 NP 498 Forms viral capsid; regulator 
of RNA synthesis 
6 1432 NA 454 Major surface glycoprotein; 
antigenic determinant; 
cleavage of sialic acid 
7 1002(MP) M1 252 Interactions with M2 and 
envelope proteins 
M2 97 Ion channel activity 
8 865(NS) NS1 230 mRNA processing in host 
cell; suppression of immune 
response; reduction of 
apoptosis 
NS2 121 Nuclear export of 
nucleocapsids by interacting 
with M1 
Table 1: Negative sense RNA segments and the corresponding proteins of influenza A virus. Lengths of 
the segments taken from reference strain A/Helsinki/100/2013(H1N1) (Briedis 2011, Yewdell, Ince 2012). 
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Replication cycle 
Attachment and nuclear transport 
Unlike most RNA viruses, Orthomyxoviruses replicate in the cell nucleus. The replication 
cycle begins when type I transmembrane protein HA binds to the receptors on epithelial cells 
containing sialic acid. Hemagglutinin functions not only in cell attachment but also acts in 
viral entry into the cell via not fully understood fusion pathway. Proteases cleave HA into 2 
subunits leading to their activation. HA1 contains sialic-acid binding domain and is presented 
on the surface of the virus particle while HA2 is attached to the viral envelope and contains 
hydrophobic fusion peptide (Briedis 2011).  
After successful binding, virions in general can enter the cell by four mechanisms: via 
clathrin-coated pits, caveolae, macropinocytosis or by non-clathrin, non-caveolae pathway. 
Clathrin-mediated internalization is the primary pathway for influenza type A viruses. Once 
internalized, the particles travel via endosomal vesicles where the drop of pH induces 
conformational change in hemagglutinin (Figure 1). This states the beginning of the 
uncoating of viral particles. The conformational change of HA2 N-terminus moves the fusion 
peptide out of HA hydrophobic area to incorporate into the endosomal membrane. Resulting 
structural shift of many HA proteins leads to the formation of a pore and release of virus 
particle into the host cell cytosol (Briedis 2011, Palese, Shaw 2001).  
The release of viral ribonucleotide complexes (consists of viral RNA, NP and three 
polymerase proteins) is facilitated by M2 protein, highly selective transmembrane ion 
channel, which allows H+ ions to penetrate the membrane. M2 channel is formed by four 
parallel α-helices lining in a tetrameric fashion that creates a small pore in the viral envelope 
(Figure 1). Its main functional element is a conserved (present also in influenza B and C 
viruses) His-XXX-Trp motif (X is any amino acid). Decline in endosomal pH induces proton 
entry via M2 ion channel and weakens interaction of M1 with vRNPs leading to the 
disruption of protein-protein interactions. The timing of the release of vRNPs depends on 
pH-mediated transition of the HA molecules involved (Briedis 2011, Chizhmakov, Geraghty 
et al. 1996).  
vRNPs contain viral RNA segments that are wrapped in a helical conformation with NP 
proteins (one subunit binds ~20 nucleotides of viral RNA). RNA polymerase protein PB1 is 
bound to the 13 nucleotide long conserved regions at both ends of the viral RNA. NP and 
polymerase proteins interact with cellular importin-α followed by the binding to nuclear pore 
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complexes (NPC) facilitating the entry of influenza virus genomes into the nucleus (Briedis 
2011). 
The overall cascade of the replication cycle is the following: viral genomes are transported to 
nucleus for transcription, mRNAs are exported to the cytoplasm for translation, subsequent 
proteins are transported back to the nucleus where they direct viral genome replication and 
form vRNPs which are again transported back to the cytoplasm via NPC for virion assembly 
at the plasma membrane (Briedis 2011).  
 
Transcription of viral RNA and translation of proteins 
In the host cell nucleus, negative-strand vRNA is used for the synthesis of both capped, 
polyadenylated viral mRNAs and full-length positive-strand RNAs, also known as 
complementary RNA (cRNA) (Figure 1). Viral genomes are transcribed using fragments of 
cellular mRNAs as primers for mRNA synthesis initiation. Viral PB2 protein recognizes 5’ 
cap structure on eukaryotic mRNAs and binds to it. PB1 acts as a nuclease, cleaving ~10 
nucleotides of the cellular mRNA starting from the 5’ cap structure. This process is also 
called “cap snatching”. The capped RNA segment (with PB2 still attached) acts as a primer 
for transcription initiation. PB1 acts as an RNA polymerase adding ribonucleotides to the 
template RNA. This process is regulated by a cleaved RNA segment bound to the 3’-teminal 
U residue on genomic RNA. Unlike other RNA viruses, Orthomyxoviruses can make capped 
mRNA without capping enzymes but are dependent on operating cellular RNA synthesis 
(Briedis 2011, Palese, Shaw 2001). 
Termination of transcription is a result of the bound PB1 polymerase stuttering on the 5’ 
terminal of the template vRNA poly(A) stretch which blocks further RNA synthesis (Briedis 
2011).  
Six out of eight transcribed mRNAs are immediately exported to the cytoplasm and 
translated by cellular ribosomes. Two mRNAs are further processed: mRNAs encoding 
matrix and nonstructural proteins contain splicing sites that are recognized by nuclear 
splicing machinery. The ratio of spliced M2 and NS2 mRNAs ratio to their unspliced 
counterparts is approximately 9:1 resulting in higher amounts of M1 and NS1 proteins. Viral 
mRNAs are translated to proteins by cellular ribosomes. Host cell factors contributing to 
viral mRNA translation eIF4A, eIF4e, eIF4G are required for the binding of viral mRNA to 
ribosomal subunits (Briedis 2011).  
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Replication of viral RNA genome 
During viral genome replication full-length vRNA (-) and cRNA (+) strands are synthesized.  
The switching from primed (mRNA transcription) to unprimed (RNA genome replication) 
RNA synthesis depends on the presence of free NP protein which interacts with viral RNA 
polymerase complex and 5’ and 3’ ends of the viral genome. The balance between them 
depends on the amound of NP present in the nucleus, the levels which are dropped during 
genome replication (Sidorenko, Reichl 2004).  
Unlike in viral transcription where RNA polymerase subunits PB1 and PB2 mediate the 
synthesis of viral mRNAs, PB1 and PA are required for genome replication. The latter copies 
the viral genome directly from 3’ terminus of the genomic segment without an intervening 
primer. Synthesized plus-strand copy is complexed with NP protein to form antigenomic 
RNAs (positive sense). The synthesis of cRNAs is not terminated at the poly(U) strech, 
generating full-length plus-strand copy of the segment. The cRNA lacks both the 5’ capped 
primer and 3’ poly(A) tail. Both the genomic minus-strand RNAs as well as antigenomic 
plus-strand RNAs can be used as templates for further vRNA synthesis as well as assembly 
of vRNA complexes. (Sidorenko, Reichl 2004, Briedis 2011).  
 
Export of viral genome from the nucleus 
Cellular nuclear export machinery aided by viral adaptor proteins is necessary to export 
vRNP complexes out of the nucleus. These complexes are bound to NP protein via sugar 
phosphate backbone and are too large for transport via passive diffusion. Nuclear export 
begins when imported M1 protein binds to newly formed nucleoparticles. NS2 with its 
nuclear export signal binds to the matrix/ribonuclear complex. It acts as a signal transducer 
to lead the protein export system to transport vRNPs to the cytoplasm via nuclear pores 
(Neumann, Hughes et al. 2000, Briedis 2011).  
 
Molecular virus and host cell interactions 
Viral NS1 plays a central role in counteracting host cell processes that try to interfere with 
viral replication. NS1 protein has several functional domains. The non-RNA binding domain 
inhibits cleavage and polyadenylation specificity (CPSF) and poly(A)-binding protein II 
(PABII) proteins responsible for the efficient 3’ end cleavage and polyadenylation of host 
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mRNAs in the nucleus. The synthesis of viral mRNA is not affected because their 
polyadenylation occurs by a separate mechanism. Most cellular pre-mRNAs are degraded 
due to the cap-binding and endonuclease activity of influenza PB1 and PB2 proteins 
(Nemeroff, Qian et al. 1995, Palese, Shaw 2001, Briedis 2011). 
dsRNA-binding domain of NS1 interferes with host pathways in influenza infections. NS1 
blocks innate cellular antiviral responses by inhibiting pattern recognition receptor pathways 
(RIG-1 interferon pathway) and suppresses double-stranded, RNA-dependent protein kinase 
(PKR) and 2’,5’oligo(A)synthetase/Ribonuclease L). NS1 also activates the 
phosphatidylinositol-3-kinase (PI3K)/Akt pathway leading to suppression of apoptosis 
(Briedis 2011).  
PB1-F2 is a 90 amino acid long recently described protein that is translated from PB1 
segment in an alternative reading frame. It resides in mitochondria and has been shown to 
overcome host immune response therefore enhancing pathogenicity. It is also believed that it 
increases apoptosis in host immune cells (Briedis 2011). 
 
Assembly of virions 
Viral HA, NA and M2 proteins are folded in host endoplasmic reticulum (ER) (HA and NA 
are also glycosylated) after which they are transported to the Golgi apparatus. Inside there, 
HA and M2 cysteine residues are palmitoylated, followed by the cleavage of hemagglutinin 
to HA1 and HA2 subunits by furin protease. Modified proteins are directed to the assembly 
site and assembled on the apical plasma membrane of polarized cells. They accumulate in the 
cholesterol rich membrane region named lipid rafts – believed to be the site of virion 
formation. Assembly and lipid raft association signals of HA and NA reside in their 
transmembrane domains.  The mechanism behind the assembly of virions could be explained 
by the interactions of the cytoplasmic tails of HA, NA where M1 binds to serve as a docking  
site for cellular transport (Briedis 2011).  
Orthomyxovirus virions contain one copy of each genome segment. Each copy is 
incorporated into a virus particle during viral budding. Viral proteins interact with specific 
vRNA sequences that are added to the formed viral particles one by one (Briedis 2011). 
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Function of neuraminidase 
Neuraminidase is a type II transmembrane protein that acts as an antagonist to hemagglutinin 
by cleaving the terminal of N-acetyl neuraminic acid (sialic acid) from mucoproteins, cell-
surface glycoproteins and glycolipids. NA reverses the binding of HA by cleaving the bound 
sialic acid residue. This relationship helps influenza viruses to bind and release abundant cell 
receptors in the respiratory tract to maximize infection efficacy (Briedis 2011). 
 
Figure 1: Influenza life cycle. The virus binds to the sialic-acid containing receptor on the cell surface and is 
endocytosed . Low endosomal pH triggers a cascade that leads to viral membrane fusion and the release of the 
viral ribonucleoprotein complexes into the cytosol of the host cell afterwhich vRNPs are transported into the 
nucleus via nuclear pore complex (NPC). Once in the nucleus, the negative-sense viral RNA (vRNA) is 
transcribed into messenger RNA (mRNA) by cellular own primer/oligonucleotide mechanism. Replication 
starts when a positive-sense copy of the vRNA (also complementary RNA or cRNA), is made and used as a 
template to produce more vRNAs. The viral protein complexes and ribonucleoproteins are assembled into viral 
particles. Abbreviations: cRNP – complementary ribonucleoproteins, F2 – cleaved variant of PB1, also called 
PB1-F2, HA – hemagglutinin, NA – neuraminidase, NS1 – nonstructural protein 1, NP – nucleocapsid protein, 
NEP – nuclear export protein, ER – endoplasmic reticulum, mRNP – messenger ribonucleoproteins, vRNP -  
viral ribonucleoproteins (Palese, Shaw 2001). 
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Human host factors in influenza replication  
König et al. analysed cellular co-factors in early-stage influenza infection by whole-genome 
RNAi approach and identified 295 cellular proteins. These include proteins necessary for 
viral entry into the host cell: vacuolar ATPase (vATPase), four out of seven COPI complex 
subunits, FGFR and GSK3-beta. Other identified proteins include those responsible for virus 
replication inside the cell (proteases and CaM kinase II beta or CAMK2B) and the ones 
important in phophatase activity, ubiquitination and kinase-regulated signaling pathways. 
Results showed that silencing of vATPase and CAMK2B had inhibitory effects on influenza 
virus replication. For successful virus replication, several host factors are needed (Konig, 
Stertz et al. 2010).  
 
Immune response 
Immunological innate cell mediated responses provide initial short-term protection against 
influenza infection. Main defense against influenza A virus infection is the production of 
chemotactic (RANTES, MIP-1-α, MCP-1, MCP-3 and IP-10), pyrogenic (fever inducing) 
pro-inflammatory (interleukins IL-1α/β, IL-6, IL-18 and TNF-α) and antiviral cytokines 
(interferons) in the site of infection by host leukocytes and epithelial cells. These factors are 
responsible for the onset of primary clinical symptoms. Important antiviral cytokines 
secreted are type I interferons (IFN-α/β) whose functions are to induce antiviral proteins such 
as protein kinase R (PKR) and to activate natural killer (NK) cells during the early stage of 
infection (Julkunen, Sareneva et al. 2001, Gazit, Gruda et al. 2006).  
Immune response of respiratory epithelial cells is directly contributable to Toll-like receptor 
3 (TLR3) expressed on pulmonary epithelial cells. These receptors sense double-stranded 
RNA which stimulates cytokine production. Primary innate immune response has also been 
shown to be dependent on TLR8 sensing single-stranded RNA (Guillot, Le Goffic et al. 
2005).  
In order to replicate vRNA in infected cells, influenza viruses counteract the innate immunity 
responses. One important protein for this is the viral NS1. For example downstream 
signalling pathways activating transcription factors IRF-3, NF-κB, and AP-1 leading to 
production of antiviral cytokines are prevented via by NS1. It binds to viral dsRNA therefore 
preventing recognition by innate immunity receptors (Briedis 2011, Donelan, Basler et al. 
2003). 
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Cytokine secretion via innate immunity response is a prerequisite for the adaptive immune 
response. Lymphocytes are activated by co-stimulatory factors induced by the innate immune 
system (Kamps, Hoffmann et al. 2006, Pawelek, Huynh et al. 2012). Influenza infection 
eventually leads to both humoral (B-cell) and cellular immune (cytotoxic T-cell) responses. 
During humoral immunity B-cells produce antibodies (IgG and IgA) against viral surface 
glycoproteins HA and NA as well as against M and NP proteins. Cytotoxic CD8+ T-cells 
recognize and eliminate infected host cells (Kamps, Hoffmann et al. 2006).    
Influenza viruses have also a strategy to counteract these adaptive immunity responses. Virus 
has important immune targets, five antigenic sites (antigenicity is defined as the feature of a 
substance or a gene to stimulate antibody production) determined by mouse monoclonal 
antibodies and defined as common Ca1, Ca2 and Cb and strain specific Sa and Sb. Influenza 
viruses mutate fast on these sites to avoid recognition by host antibodies, since 1918 these 
sites have shown most variable amino acid compositions due to antibody-mediated immune 
pressure. Many of these mutations have been associated with the enhanced viral replication 
(S183P, I191L) (numbering without signal peptide) and more virulent phenotype (D127E, 
S183P, D222G) (Strengell, Ikonen et al. 2011).  
 
Characteristics of influenza virus induced diseases 
 
Virus transmits in humans via the respiratory route by either coughing or sneezing. Infection 
can proceed asymptomatically, be severe or even fatal. Deaths occur more frequently in 
elderly, infants and chronically ill patients and are increased by secondary infections. 
Symptoms of influenza infection are fever, headache, cough and sore throat, nasal congestion, 
sneezing and whole- body muscular pain. On rare occasions heart complications like myositis, 
myocarditis may arise, and also toxic shock syndrome and Reye’s syndrome may develop in 
patients diagnosed with influenza infection (Lamb 2008). 
The virus replicates in the upper and lower respiratory tract mucosal cells causing the loss of 
ciliated epithelium and inducing systemic inflammation by the production of immune system 
signaling factors like interferons and cytokines. Strongest symptoms appear 2-3 days after 
infection and the virus is usually cleared from the system within a week. Primary infection in 
children lasts approximately 13 days (Lamb 2008, Briedis 2011). 
Leading cause of severe morbidity and mortality in influenza cases is bacterial secondary 
infection (co-infections) resulting in enhanced pneumonic illness (Joseph, Togawa et al. 
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2013). The most common causes for community-acquired pneumonia are Streptococcus 
pneumoniae, Staphylococcus aureus and Haemophilus influenzae.  S.pneumoniae is mostly 
associated with influenza infections (Brundage 2006). In the year 2009 pandemic caused by 
A(H1N1)pdm09, 28% of the influenza cases in New York had bacterial co-infections, most 
common being S.pneumoniae, followed by Staphylococcus pyogenes (Lee, Wu et al. 2010).  
 
Genetic susceptibility and severity of influenza infection 
Influenza virus induced diseases can have different outcomes, however, the underlying 
factors determining the extent and severity are not fully understood. It has been suggested 
that viruses could be distinguished by “intrinsic virulence” (transmission efficacy or ability 
to cause symptomatic infection) (Dolin 2013).  
There are many determinants that could affect the virulence, transmissibility and severity of 
influenza infection and contribute to more devastating outcome for the patient:  
1.  Highly virulent virus (e.g. H5N1, H7N9) 
2.  Fast replication of the virus 
3.  Excessive inflammatory response 
4.  Poor innate antiviral immunity 
5.  Bacterial secondary infection 
6.  Underlying chronic diseases 
Determining the causative factors requires thorough understanding of the infection process 
and its outcomes (Julkunen, Ikonen et al. 2012). 
One regulator of infection is host genetics. Identification of occurring polymorphism allows 
the assessment of populations with high-risk influenza infection. Knowledge on genetics can 
also provide targets for new therapeutics. There are some identified SNPs in host genomics 
that could increase susceptibility to influenza infection (table 1). Adverse outcomes can be 
associated with genetic polymorphisms that affects host immune responses (Keynan, Malik 
et al. 2013). 
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Gene Function  Polymorphism Functional 
significance 
Reference 
CCR5 
(chemokine-
receptor 5) 
Leukocyte 
chemotaxis 
in 
chemokine 
response 
CCR5Δ32  Increased allele 
frequency in Canadian 
H1N1 Intensive care 
unit (ICU) patient cases 
(Keynan, 
Juno et al. 
2010) 
 
KIR (killer-cell 
immunoglobulin 
like receptor) 
Factor 
activating 
NK cells 
2DL2/L3  Also shown in 
Canadian H1N1 ICU 
cases 
(La, 
Czarnecki et 
al. 2011) 
 
IFTIM3 
(interferon-
induced 
transmembrane 
protein 3) 
Restricting 
influenza 
virus 
replication 
rs12252 altered 
splice acceptor 
Increased in 
hospitalized cases of 
A(H1N1)pdm09 in 
England and Scotland 
(Boon, de 
Mutsert et al. 
2002) 
 
FcγRIIa, IGHG2 
(Immunoglobulin 
G Fc receptor 
subunit) 
Complement 
activation 
IGHG2 *n/*-n 
FcγRIIa-
R131H 
IgG2 subclass 
deficiency reported in 
association with severe 
H1N1 cases 
(Zuniga, 
Buendia-
Roldan et al. 
2012) 
 
Table 1 Genetic polymorphisms associated with influenza type A H1N1 susceptibility and severity. Note: 
CCR5Δ32 was found in 55,6% of patients confirmed with severe H1N1 infection (Keynan, Malik et al. 2013).  
 
Viral genetic modifications are another factor contributing to the severity of the disease. 
Many studies have reported genetic alterations in the virus genome that could cause more 
severe disease outcome. The mostly studied is the D222 polymorphism in HA protein 
(numbering without the signal peptide) being potential virulence marker associated with 
severe influenza infection worldwide  - presumably due to the area’s binding affinity to α-
2,3-linked sialic acid receptors present in human lung epithelial cells (Drews, Pabbaraju et al. 
2011, Yasugi, Nakamura et al. 2012, Anton, Pozo et al. 2012). This substitution is in the 
antigenic site of hemagglutinin and other mutations have also been reported in the same area 
(Yasugi, Nakamura et al. 2012). 
Mutations leading to antiviral resistance can also affect the outcome of the virus infection. 
H275Y and I223R mutations in neuraminidase protein have been shown to cause resistance 
to neuraminidase inhibitors (NAI). However, these are mostly found in immunocompromised 
patients (LeGoff, Rousset et al. 2012).  
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Treatment and prevetion 
Currently there are many antiviral drugs available that mostly target either NA or M2 
proteins (Min, Subbarao 2010).  
Oseltamivir (marketing name Tamiflu) is a selective neuraminidase inhibitor of the influenza 
viruses A and B. Upon exposure to the drug, the influenza particles aggregate on the surface 
of the host cell, thereby restricting the infection within the tissues and mucosal membranes 
(Figure 1) (McNicholl, McNicholl 2001). Oseltamivir is an ethyl-ester prodrug that results in an 
active form oseltamivir carboxylate [3R,4R,5S]-4-acetamido-5-amino-3-(1- ethylpropoxy)-1-
cyclohexene-1-carboxylate phosphate (Lew, Chen et al. 2000). 
Zanamivir (marketing name is Relenza) is a neuraminidase inhibitor consisting of 2-deoxy-2, 
3-dihydro-N-acetylneuraminic acid. It is administered either intranasally or inhaled (Lamb 
2008). 
Peramivir is a FDA unapproved, neuraminidase inhibitor of influenza type A and B viruses. 
In vitro potency seems to be better than with zanamivir and oseltamivir carboxylate based on 
generally lower maximal effective concentration (EC(50)) (Sidwell, Smee 2002).  
Amantadine (with the marketing name Symmetrel) is an inhibitor of M2 H+ proton-seletive 
ion channel. Rimantadine is a methyl derivative of amandatine. The use of ion channel 
blockers is not relevant because drug-resistant variants are globally abundant (Lamb 2008).  
Alternative treatment options could arise from the knock-down studies identifying cellular 
proteins important in viral life cycle. Cellular targets for the treatment of influenza infections 
include viral particle binding, endosomal trafficking, viral replication inside the cell and 
vesicular transport (Figure 2) (Min, Subbarao 2010). 
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Figure 2: Viral and host cellular targets for anti-influenza drugs in the context of the replication cycle of 
influenza virus. Influenza A virus replication steps are shown in green. Cellular pathways essential for 
completion of the viral replication cycle are shown in red. Currently, the viral M2 ion channel protein and 
neuraminidase are the only two targets of influenza antiviral drugs (gray boxes) licensed by the US Food and 
Drug Administration. Adamantane drugs  block M2 protein during uncoating of the virus. Zanamivir and 
oseltamivir target neuraminidase (Min, Subbarao 2010).  
 
Vaccine development 
Vaccination is the primary strategy for prevention and control of influenza virus. Eventhough 
both inactivated and attenuated vaccines are effective in the prophylaxis of influenza 
diseases, it is very important that the antigenic determinants match the circulating epidemic 
influenza viruses. Also important is the recipient’s age and health status. Inactivated vaccines 
can be divided based on their production method into egg-based, cell-based and with 
adjuvant. Their preventive efficacy is 60-80%  in children and adults. Live attenuated 
vaccines are produced either using egg-based or cell-based method. Their advantage over 
inactivated vaccines is that they can be administered intranasally (Lambert, Fauci 2010).  
Seasonal influenza vaccines are trivalent containing three viruses or their hemagglutinin 
proteins (influenza type A H3N2, influenza A H1N1 and influenza B strains). Hybrid and 
natural strains are combined in laboratory settings and adapted to grow in eggs (Matthews 
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2006). Plasmid-based reverse-genetics is used to shorten the time frame of production 
(Hoffmann, Neumann et al. 2000). 
New technologies in vaccine development are necessary to increase the capacity in the event 
of a pandemic. Next generation vaccine production involves methods like the use of 
recombinant proteins (HA is cloned and purified), virus-like particles (vectors containing 
HA, NA and M1 genes are cloned and purified), viral vectors (use of “carrier” viruses that 
cannot cause disease), DNA-based vaccines (DNA plasmids containing viral segments) and 
universal vaccines (also known as “common-epitope” vaccine) (Lambert, Fauci 2010).  
In Finland approximately 5.3 million vaccines were imported in the last pandemic years 
2009-2010 (Lyytikainen, Kuusi et al. 2010). 
 
Evolution and epidemiology 
Influenza viruses cause annual epidemic (seasonal) outbreaks which are generally due to a 
subtype of a virus already circulating among people. Pandemics (outbreak of global 
proportions) however, are generally caused by novel subtypes and results in higher number of 
fatalities. One characteristic of a pandemic influenza subtype is that it needs to be easily 
transmittable among humans (Lyytikainen, Kuusi et al. 2010) 
Genetic variability that results in a new virus strains emerges from antigenic changes. These 
evolutionary changes occur in two ways: 
1)  Antigenic shift- resassortment of segments due to mixture of different viral subtypes 
2)  Antigenic drift- accumulation of point mutations 
Antigenic drifts result from adaption to neutralizing antibodies and are also called antibody 
escape mutants. These variants occur with the frequency of less than 1% per year. Antigenic 
shift however is more prevalent in the population (Briedis 2011, Lamb 2008). 
 
Influenza virus pandemics and outcomes 
First recorded global (and with the most fatalities) influenza viruses outbreak (also called the 
“Spanish Flu”) occurred in 1918-1919 causing death of at least 40 million people mostly due 
to secondary bacterial pneumonias (Figure 3) (Johnson, Mueller 2002). Detailed studies of 
the virus strain are limited due to the lack of sample material. However lung tissue sample 
obtained from 1918 suggest „unusual avian precursor“ for the virus. Eventhough the HA was 
 20 
 
of avian origin, the 1918 influenza could still bind to human receptors (Reid, Taubenberger 
et al. 2004).  
Asian influenza virus in 1957 (Figure 3) consisted of  3 segments from avian virus (H2, N2 
and PB1) and other segments from previously circulating human virus. The global mortality 
was estimated to be 1-2 million deaths (Scholtissek, Rohde et al. 1978, Kamps, Hoffmann et 
al. 2006).  
Hong Kong influenza virus (H3N2) in 1968-1969 had HA and PB1 segments  of avian virus 
origin descending from H2N2 through antigenic shift (Figure 3). The acquisition of avian 
surface antigens allowed these viruses to escape from human immune response. The death 
rate was estimated to be the mildest with approximately 1 million deaths in the USA 
(Scholtissek, Rohde et al. 1978, Kamps, Hoffmann et al. 2006).  
 
 
Figure 3: Recorded human influenza virus pandemics since 1885 (early sub-types inferred). Source: 
Europan Centre for Disease Prevention and Control (ECDC) 2009. Spanish influenza virus H1N1 pandemic in 
1918 was caused by human- transmittable avian virus.  Asian influenza subtype H2N2 in 1957 was a reassortant 
between H1N1 genes PB1, HA and NA. In 1968, another reassortant, H3 avian virus (segments PB1 and HA) 
and the remaining gene segments from an H2N2 human virus, emerged as a new pandemic strain (Hong Kong 
influenza; H3N2 subtype). Latest pandemic was caused by reassortant containing viral segments from human, 
duck and swine (subtype H1N1) (Nicoll 2010, Horimoto, Kawaoka 2005). 
 
Influenza A(H1N1)pmd09 
On June 2009, the World Health Organisation (WHO) indicated that a novel influenza virus 
had entered into pandemic stage (Briedis 2011). A(H1N1)pdm09 derives from the assortment 
of classical swine and avian influenza of North American lineage, human seasonal H3N2 
lineage and Eurasian swine lineage therefore combining the genes of human, swine and avian 
origin (European Centre for Disease Prevention and Control 2009). 
 21 
 
In Finland the first reported influenza A(H1N1)pmd09 infections  in individuals returning 
from a trip from Mexico were diagnosed on May 10 2009. From May- July 2009 nearly 90% 
of infections, and in August 2009 ~60% of infections were diagnosed in individuals returning 
from abroad. By December 2009, the virus had spread all across the country (Ikonen, 
Haanpaa et al. 2010).  
Basic epidemiological studies show that younger people (between ages 10-29) were more susceptible to the 
virus and nearly 80% of the cases were detected in patients under 30 years of age . This can be explained by 
the adaptive immune system in elderly acquired from previous influenza-like diseases (A(H1N1)v Ewgoi 
2009, Dawood, Jain et al. 2009). There was equal distribution of influenza incidence in males and females 
(European Centre for Disease Prevention and Control 2009). The 2009 influenza pandemic  had 
similarities with the previous pandemics. However, differences were found in the higher incidence of 
severe infections in children and pregnant women. Furthermore, residual immunity of elderly was 
shown to explain their lower mortality rates compared to other age groups.  
Another uncommon feature of influenza infections compared to previous pandemics was the existence of 
sudden acute illnesses and deaths from acute respiratory disease syndrome (ARDS) (European Centre 
for Disease Prevention and Control 2009, Jain, Kamimoto et al. 2009). European Centre for Disease 
Prevention and Control (ECDC) has named risk groups for the severe infection related to 
A(H1N1)pdm09 pandemic in 2009. These include:  
• People with chronic conditions such as cardiovascular, respiratory, metabolic (notably 
diabetes), renal and hepatic diseases, immunodeficiency or neuromuscular conditions  
• Pregnant women 
• Children under two years of age 
The clinical features of mild and severe A(H1N1)pmd09 cases differ. Uncomplicated mild infections 
were often followed by gastro-enteric symptoms usually seen in seasonal influenza epidemics (Centre 
of Disease Control and Prevention 2009). In severe infections one notable feature was that the 
patients became very sick in a short time period. Co-infections (viral pneumonias and bacterial 
infections) were detected but less common in the pandemic cases than in seasonal ones. Usual cause 
of death in severe influenza infections was progressive organ failure (World Health Organisation 
2009).  
In Finland the peak of pandemic influenza A(H1N1)pdm09 cases occurred in 2009/2010 
(Figure 4). The National Infectious Disease Register reported the highest incidence of 
A(H1N1)pdm09 in Northern-Finland where also the first cases of this strain were reported 
and lowest in the South-East region of the country, including Helsinki region. Before the 
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outbreak of A(H1N1)pdm09 in 2009, the most relevant influenza strain amongst the 
population was H3N2 (Lyytikainen, Kuusi et al. 2010). 
A total of 7,669 laboratory-confirmed pandemic influenza A(H1N1)pdm2009 cases were 
identified in Finland from May 2009 until March 2010. The highest morbidity was amongst 
children, lowest in elderly (Lyytikainen, Kuusi et al. 2010). In the study by Ikonen et al. 
lower infection incidence in elderly was partly explained by the cross-reactive immunity 
when antibodies originating from earlier infections were discovered in their system (Ikonen, 
Haanpaa et al. 2010). 
 
 
Figure 4: Yearly influenza epidemics in Finland. Strongest effect on the national Finnish health occurred in 
2009 with the A(H1N1)pdm09 pandemic outbreak (graph from Ilkka Julkunen). 
  
Genetic profiling has revealed mutations in the genome of A(H1N1)pmd09 that could have effect on 
the severity of the disease. One such is previously mentioned D222 found in hemagglutinin and 
statistically present more in severe cases than in mild ones (Ikonen, Haanpaa et al. 2010, Ruggiero, 
De Rosa et al. 2013). 
To date over 40 isolates of the pandemic virus A(H1N1)pdm09 resistant to oseltamivir have 
been reported. All the isolates have been susceptible to zanamivir. Amantadine is not used in 
the treatment of influenza infections because all the emerging strains contain resistance 
marker (S31N) for amantadine (World Health Organisation 2009). 
 23 
 
Aim of the study  
 
The aims of this study: 
 
• Find and apply fast and precise method for sequencing large amount of virus isolates 
from patient samples 
• Identify susceptibility factors for severe influenza A infections 
 
• Describe the phylodynamics of influenza A(H1N1)pdm09 virus in Finland. 
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Materials and methods  
 
Whole-genome sequencing of virus samples is necessary to investigate the full genomes of 
influenza viruses for mutational and evolutionary studies. This process was done at the 
Institute for Molecular Medicine Finland (FIMM) Sequencing Unit at the Faculty of 
Medicine, University of Helsinki, using Illumina technology based next-generation 
sequencing. Samples were obtained from patients diagnosed with influenza A(H1N1)pmd09. 
Viruses were propagated, RNA extracted and amplified and two 96-sampled libraries were 
prepared for sequencing. 
 
Patient sample collection 
Ethical approval for handling patient samples was provided by different institutions: 
 Handling of native and recombinant influenza virus strains in BSL2 laboratory at 
FIMM (21/M/09). 
 Sample collections were approved by the ethical review committee of the University 
Helsinki Central Hospital, Finland. 
 Anonymized blood and NPA samples of influenza A virus-positive individuals were 
collected and patients gave informed consent that their samples can be used in 
scientific research (DNROs 165/13/03/00/2011 and 244/13/03/01/2012). 
 
Samples (total of 125 mild and 28 severe A(H1N1)pdm09 samples, out of which 6 severe 
cases were sequenced previously and 20 seasonal samples) were obtained from Haartman 
Institute Helsingin ja Uudenmaan sairaanhoitopiirin laboratoriokeskus (HUSLAB) Unit and 
from Finnish National Institute For Health and Welfare (THL). Nasopharyngeal aspirates 
(NPA) were collected and stored as aliquots at -80°C at FIMM. Annotations and patient 
information for each sample were provided. 
 
 
Propagation in MDCK cells 
 
The yield of viral RNA in NPA samples is too low for sequencing, thereby propagating 
viruses in MDCK (Madin-Darby canine kidney epithelial cells) is necessary to amplify the 
viral RNA (cells were provided by collaborative laboratory Professor Richard Elliott, 
University of St Andrews, United Kingdom). In order to propagate viruses, MDCK cells need 
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to be prepared to form a confluent monolayer on culture vessel. This is achieved by 
passaging cells on 96-well plates and T75 (the floor area of the flask is 75cm2) flasks. For 
this, MDCK cells were washed once with PBS followed by trypsin treatment at 37°C for few 
minutes to detach cells from the bottom of the flask. Detached cells were suspended in 
Dulbecco’s modified Eagle’s growth medium (DMEM Eagle; GIBCO, Carlsbad, California) 
supplemented with 10% fetal bovine serum (FBS; GIBCO, Carlsbad, California), 4 mM L-
glutamine and 100 units/ml of penicillin/streptomycin antibiotic solution to support cell 
growth ad prevent bacterial growth. For 96-well plates the volume was 100µl per well. With 
cells diluted 1:10 (meaning 1 part of cell suspension and 9 parts of medium), it took 3-5 days 
for them to reach confluency at +37°C humidified 5% CO2/ 15% O2  incubator. Confluency 
was determined visually with light microscope (Leica DM Inverted Light). 
 
For influenza virus propagation, 1:100 ratio of NPA samples in virus growth mediawas added 
to the confluent MDCK cells. In order to support the growth of influenza viruses, N-p-Tosyl-
L-phenylalanine chloromethyl ketone treated trypsin (TPCK-trypsin) was added to make the 
progeny virions infectious (cleavage of the HA so that it could bind to sialic acid present on 
the surface of cells). Instead of FBS, bovine serum albumin (BSA) was added to viral growth 
media (DMEM Eagle). To prevent the growth of bacterium, fungi or mycoplasma (general 
contamination) 100 μg/ml normocin was added to the media, as well as antibiotics 
streptomycin and penicillin. 
 
Two days post infection, the efficacy of infection (replication efficacy indicated by infection-
induced cell death) was measured by quantifying the ATP (present in metabolically active 
cells) with CellTitre Glo® (CTG) Luminescent Cell Viability Assay (Promega) using 
manufacturer’s protocol. Smaller quantified result of ATP shows better viral infection on 
MDCK cells. Survival of the cells was also visually monitored with light microscope (Leica 
DM Inverted Light LED Fluorescence).  
 
RNA extraction 
 
High-throughput RNA extraction was done with RNeasy 96 kit (Qiagen) using 
manufacturer’s protocol. This method enables fast and high-throughput extraction of viral 
RNA from large number of samples using silica membranes and centrifugation system. 
Before the lysis step of viral samples, 2 microlitres of proteinase K was added to each sample 
to inhibit endogenous RNases. Proteinase K-treated samples were stored at -20°C to prevent 
degradation of RNA. Viral genome extraction was proceeded and handled with care in a clean 
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environment to avoid any possible contaminations. 
 
RT‐PCR 
 
Comparison of two-step reverse transcription polymerase chain reaction (RT-PCR) and one-
step RT-PCR was conducted to test which method amplifies all of the 8 viral RNA (vRNA) 
segments equally (meaning with the same concentration of each segment). The difference of 
methods is in the number of stages: with one-step RT-PCR reverse transcription and PCR 
stage are done in the same tube. In two-step RT-PCR they are conducted separately. For one-
step method, Invitrogen SuperScript™ One-Step RT-PCR system (Life Technologies) was 
used and for two-step method different solutions and enzymes were purchased from Life 
Technologies. T7 universal primers (5’- TAATACGACTCACTATAGGG-3’) were chosen 
for two-step PCR reaction as universal primers for full-length amplification of all segments, 
whereas primers from Watson et al. were used for one-step RT-PCR reaction (see below). 
For two-step RT-PCR 1000U Revert Aid reverse transcriptase was used with the strategy described 
by Baillie et al. (Baillie, Galiano et al. 2012). After primary tests, one-step RT-PCR was chosen 
for viral RNA reverse transcription and following amplification due to better amplification 
results. After optimization the final experiment was conducted with the following conditions: 
 
  Temperature Time  
Reverse 
 
transcription 
 42°C 15 min  
 55°C 15 min  
 60°C 5 min  
Denaturation  94°C 2 min  
Primary 
 
amplification 
Denaturation 94°C 30 sec 5 cycles 
Annealing 45°C 30 sec 
45°C-68°C 46 sec; 0,5°C/sec, 
 
slow ramp 
Extension 68°C 3 min 
Secondary 
 
amplification 
Denaturation 94°C 30 sec 30 cycles 
Annealing 57°C 30 sec 
Extension 68°C 3 min 
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  68°C 5 min  
 
 
Mixture: 
 
 
RNase-free water 
 
 
- 13,8 µl 
 RNA - 10 µl 
 Primers - 0,1 µl (each) 
 Buffer - 25 µl 
 Enzyme mix - 1 µl 
The enzyme mix contains High-Fidelity Platinum® Taq DNA polymerase and the buffer 
doesn’t have magnesium salts in it. The mixture was prepared as a mastermix. 
 
Amplification was done with two sets of primers: one with common influenza A primers 
named common_uni12 (5’-GCCGGAGCTCTGCAGATATCAGCRAAAGCAGG-3’) and 
common_uni13 (5’-CAGGAAACAGCTATGACAGTAGAAACAAGG-3’) that favorably 
amplify longer vRNA segments (PA, PA-X, PB1 and PB2) and one with common influenza 
A primers named common_uni12G (5’-
GCCGGAGCTCTGCAGATATCAGCGAAAGCAGG- 3’) and common_uni 13 that 
amplify shorter vRNA segments (NA, NP, HA, M1/2, NS1/2). The primer sequences cover 
the conserved sequences on both ends of the viral segments. After amplification step the 
resulted two mixtures were combined (Watson, Welkers et al. 2013). 
 
After RT-PCR all the samples were analyzed on 1% agarose gel on electrophoresis (120V) 
and visualized in a UV-chamber with ethidium bromide which incorporates into DNA. Proper 
precautions were used when handling ethidium bromide to minimize its harmful 
cancerogenous effects. Successfully amplified samples were purified from PCR mixtures, 
rechecked on 1% agarose gel on electrophoresis (120V) and submitted to FIMM Sequencing 
Unit. 
 
 
Library preparation for sequencing 
 
For sequencing all the samples were reverse transcribed into cDNA (complementary DNA) 
following dsDNA (double stranded DNA) synthesis using OneStep RT-PCR technology 
described previously. Libraries were prepared using Illumina Nextera® DNA Sample 
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Preparation Kit for generation of clustered paired-end libraries from genomic DNA. In total 
two libraries were generated in two 96-well plates. In general, the workflow was conducted 
using manufacturer’s protocol as following: 
 
 
Samples were randomly fragmented and tagged with specially engineered transposomes. Tags 
are necessary to amplify the fragments in limited-cycled PCR reaction. After completion the 
fragments also contain primer sequences and indices. Ligated sequence markers on both ends of 
the fragments were added in order to identify and concatenate them later. The markers for 
each library were generated with the dual indexing strategy with different mixture of indexes 
N701-N712 and N501-N508 so that each sample in one library would have one index 
complex. Libraries were validated and concentration measured using PicoGreen dsDNA 
Picogreen assay (Invitrogen) which identifies the concentration with DNA-specific fluorescent 
dye method. Samples were placed on Illumina chip where the adaptors ligated on both ends of 
the fragments bind to the inside of the cell channels present on the chip. Upon completion the 
samples were demultiplexed (Illumina Proprietary, 2012). 
 
 
Sequencing 
 
Total of 140 samples were sequenced with Illumina HiSeq 2000 sequencer using Illumina 
deep sequencing technology at FIMM Sequencing Unit. Total runtime was 14 days, 
afterwards demultiplexing was performed by FIMM Bioinformatical Unit. Demultiplexing 
consisted of mapping the reads using GenBank reference strain (A/California/07/2009) and 
identifying variants using institute’s own developed Variant Calling Pipeline (VCP). This 
method identifies all single nucleotide polymorphisms compared to the reference strain with 
the statistical values showing the probabilities of different nucleotides in that specific 
position. For further analysis the most dominant variants were chosen 
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Bioinformatic analysis 
 
Mutation analysis 
Sequences were rendered and concatenated to visualize whole-genomes using Ugene Unipro 
software. The order of the concatenated sequences was the following: hemagglutinin (HA), 
matrix protein (M2/M1), neuraminidase (NA), nucleocapsid protein (NP), nonstructural 
protein (NS2/NS1) and polymerase subunits (PA, PB1 and PB2). Sequence alignment was 
performed with commercially available ClustalW software: for A(H1N1)pdm09 isolates 
GenBank reference strain (A/California/07/2009) isolated from patient with severe disease, 
and for 10 seasonal samples GenBank reference strain (A/Sydney/5/1997) were used. 
Another alignment was performed with the translated sequences using Ugene UniPro 
software. Annotations and translated sequences were obtained from Influenza Virus Resource 
package annotation tool (http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html) provided by 
National Center for Biotechnology Information (NCBI). This tool is takes into consideration 
the correct reading frame for influenza genomes as well as the overlapping open reading 
frames in these viruses. Amino acid sequences of severe and mild cases were compared and 
cumulative results visualized as a histogram to determine possible correlative polymorphisms 
(appendix 1). 
 
Interesting amino acid substitutions that could alter virulence were visualized using PyMol 
software downloadable online. The latest full structures of the proteins were downloaded 
from protein databank (http://www.pdb.org/pdb/home/home.do).  
The models were analyzed using Tracer program following Bayesian statistical parameters. 
The definitions for the statistics are (Cummings 2013): 
• Mean – The mean value of the samples (excluded the burn-in). 
• Stdev – The standard error of the mean.  
• Median – The median value of the samples (excluding the burn-in). 
• 95% HPD Lower – The lower bound of the highest posterior density (HPD) interval.  
• 95% HPD Upper – The upper bound of the highest posterior density (HPD) interval. 
• Auto-Correlation Time (ACT) – The average number of states in the MCMC chain 
that two samples have to be separated by for them to be uncorrelated (i.e. independent 
samples from the posterior).  
• Effective Sample Size (ESS) –number of independent samples that the trace is 
equivalent to.  
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Phylodynamic analysis 
To study the phylodynamics of H1N1pdm09 in Finland, phylogenetic analysis was done with 
BEAST program v.1.7.5 which uses the set of probability distribution algorithms called 
Markov Chain Monte Carlo (MCMC). The goal is to estimate posterior density under 
assumptions to the likelihood of the observed viral population and phylogenetic data 
(Ratmann, Donker et al. 2012). 
 
In order for the program to generate the phylogenetic tree in relation with divergence times 
XML file was generated from the NEXUS alignments (exported from ClustalW). The 
generated file needs to contain the options of MCMC analysis and build proper evolutionary 
model. Generated input alignment was accomplished with BEAUti (Bayesian Evolutionary 
Analysis Utility) v1.7.5 program (Drummond, Rambaut 2007). Tip dates for the tree were set 
with the dates of the virus collection from patients. Sites were set with the FLU substitution 
model to generate protein phylogenetic tree and HKY substitution model to generate nucleotide 
alignment phylogenetic tree. FLU and HKY were chosen because only one organism 
(influenza virus) is present in this alignment. Four categories of gamma site heterogeneity 
model were set to allow rate variation between sites in the alignment (Goldman, Whelan 
2000). A strict clock model (uncorrelated log-normal) was chosen because of influenza 
virus’es characteristically fast mutation rate. The initial value, shape for gamma prior clock 
rate was 0.01 with the scale of 1000 by taken into consideration the exponential growth in the 
model. Clades were determined by the following criteria (according to WHO): 
• Sharing a common node 
 
• Mean percentage distances between and within clades is 1,5% 
Phylogenetic tree was annotated using the BEAST package program TreeAnnotator with 
burn-in of 100 due to high number of trees (1 000 000) generated meaning the first 1% of 
trees were eliminated. Phylogenetic tree was rendered and visualized using FigTree software. 
For a graphical output of the diagnostic information as well as summary of distributions of 
the tree Tracer program was used. 
 
In order to unmask the evolutionary dynamics of influenza, Bayesian skyline plot using 
MCMC set of algoritms (to estimate a posterior distribution) with a strict clock model was used 
for its feature to fit a wide range of demographic scenarios. The difference between other 
methods and Bayesian skyline plot is that the latter includes credibility intervals for the 
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estimated population size at every time point. The goal is to determine tMCRAs (time of most 
common recent ancestry) or in other words the divergence dates of clades using FLU 
substitution model including gamma site heterogeneity model with four categories. 
Coalescent tree prior used constant Bayesian Skyline model in a piecewise manner 
(Drummond, Rambaut et al. 2005). XML file was generated using BEAUti v1.7.5 program 
and BEAST v1.7.5 for analysis for the output for Bayesian skyline plotting. The chain length 
for both tree generation and Bayesian Skyline was 10 000 000 to allow deep optimization and 
to reduce the likelihood of high error rate. Tracer program enabled visualizing the results by 
plotting them in a time wise manner.  
 
During primary analysis of the phylogenetic trees and Bayesian plots, it became obvious that 
in addition to concatenated versions the clusters and mutation rates (interpreted as the 
substitution rate or the clock rate) of both hemagglutinin and neuraminidase were needed. To 
visually combine the Bayesian Skyline plots and phylogenetic trees, they were aligned to the 
same timescale and the start of the evolutionary change was highlighted in pink in every tree 
(appendix 2a-d). 
 
All the programs (except Ugene Unipro) used in the phylodynamic analysis were obtained from 
the internet as freeware, no licences were required. 
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Results  
 
Propagation of viruses 
For influenza viruses, the infection cycle (new viruses produced in a cell) is approximately 
12-18 hours (Sidorenko, Reichl 2004). Virus propagation was optimized in MDCK cells. The 
best virus yield was obtained when confluent MDCK cell were infected with 1:100 dilution 
of NPA sample in virus growth media and incubated for two days. Successful virus 
replication in cells was observed by visualizing cytopathic effect due to cell death by virus 
production.  In addition, cell death was quantified with measurement of ATP content of 
infected cells. All NPA samples were grown on MDCK cells and supernatant from 4th 
passage was collected and used for amplification of viral RNAs. 
 
One‐step versus two‐step RT‐PCR methods 
In order to identify the best method to amplify all of the eight influenza virus segments in 
equal amounts, two distinct RT-PCR methods were examined and optimized. One-Step RT-
PCR proved to be more effective method than two-step RT-PCR. Using the primer pair 
common_uni12G and common_uni13 the long viral segments were equally amplified with the 
smaller ones and all 8 segments were visible on agarose gel when amplified with one-step 
RT-PCR (Figure 5). One-step RT-PCR method enabled the successful amplification of 84% 
of all the samples provided by HUSLAB and THL.  
 
 
 
Figure 5: Reverse-Transcription Polymerase Chain Reaction. One‐step RT‐PCR yielded better results than 
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two‐step RT‐PCR method. For one-step RT-PCR common_uni12, common_uni12G and common_uni13 
primers were used. For two-step RT-PCR oligos for PCR step were T7 conserved primers. Abbreviations: PB1, 
PB2 and PA – polymerase subunits, HA – hemagglutinin, NP – nucleocapsid protein, NA – neuraminidase, M 
– matrix protein, NS – nonstructural protein, RT-PCR – reverse-transcription polymerase chain reaction, wt – 
wild type.  
 
Sequencing of the isolates 
Of the 140 samples submitted for sequencing 135 (including 6 previously sequenced 
samples) were used in bioinformatical analysis. The average reads per isolate was 
3686912,27 with the read length of 100bp. All of the reads were trimmed and mapped with 
the reference strain (A/California/7/2009) using BWA software which reduced the number of 
reads by 46%. Variants detected with the institute’s own developed pipeline (VCP) had on 
average 180 variants per isolate. Sequences of A(H1N1)pdm09 were submitted to Genbank 
(accession numbers KF559358 - KF560309) and GISAID databases (GISAID Isolate ID-s: 
EPI_ISL_145286-145302). Previously submitted six A(H1N1)pdm09 (accession number 
JQ409139.1-JQ409246.1, JQ409131.1-JQ409238.1, JQ409123.1-JQ409230.1, JQ173145.1 -
JQ173152.1, JQ173153.1 -JQ173160.1, JQ173161.1-JQ173168.1) were included into 
subsequent analyses. Seasonal isolates (10 samples in total) were submitted to GenBank. 
 
Phylogenetic analysis 
 
Tracer program was used to analyse both the phylogenetic trees and Bayesian Skyline Plots. 
Divergence was analysed on the basis of effective sampling size (ESS), the mean and 
credibility intervals with 10% burn-in. The statistical values of the substitution rates for the 
phylogenetic trees are shown in table 2. The difference between Bayesian probability 
interpreted by HPD (Table 2) and classical confidence intervals is that the latter enables the 
interval to cover the true parameter whereas Bayesian probability reflects a person’s 
subjective beliefs while modeling. Virus evolutionary dynamics can best be shown with 
Bayesian modeling (SAS Institute Inc 2009).  
As shown in table 2, hemagglutinin has the highest substitution rate followed by 
neuraminidase. Wide credibility intervals (HPD) indicate that mutation rate could be even 
higher. Nucleotide sequences have changed less than amino acid sequences over time 
describing their smaller effect on the viral population size.  
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 Nucleotide Protein Hemagglutinin Neuraminidase 
mean 1,30E-04 3,16E-04 1,66E-03 1,59E-03 
Standard deviation of mean 3,29E-05 3,39E-05 1,32E-04 7,16E-05 
median 1,14E-04 3,19E-04 1,64E-03 1,51E-03 
Lower 95% highest posterior 
density (HPD)  
1,14E-04 3,07E-04 1,60E-03 1,52E-03 
Upper 95% highest posterior 
density (HPD)  
4,70E-05 1,77E-04 9,11E-04 8,23E-04 
auto-correlation time (ACT) 2,98E-04 4,46E-04 2,59E-03 2,58E-03 
effective sample size (ESS) 2,04E05 1,78E05 88076,3 1,51E05 
Table 2 Statistical parameters of substitution rate/clock rate of the four Bayesian models for the creation 
of phylogenetic trees.   
 
 
The phylogenetic analysis revealed that all of the phylogenetic trees separated into 5 clades 
(A-E). Clustering did not follow the date of isolation that representatices of different clades 
were co-cistulating (appendix 1). Interestingly, viral sequences obtained from severe cases 
claded somewhat apart from the mild cases. The high standard error of the models analysed 
is due to low ESS. ESS itself is calculated by the chain length divided by the ACT. The latter 
is the estimation of samples in the trace. Low ESS can be increased when making the data set 
more dynamic by including more mild cases from different years. The burn-in has been 
excluded in the calculation of the statistical parameters. The mathematical interpretation of 
possible errors can expressed as alpha values:  
  
Phylogenetic 
trees 
Nucleotide 0,0227 
Protein 0,0304 
Hemagglutinin 0,0511 
Neuraminidase 0,0758 
Table 3 Alpha values of the Bayesian models for phylogenetic trees. The critical level for alpha value 
according to Fisher is 0,05 meaning that showing false-positive rate must not exceed 5% (Fisher 1960) .   
Alpha values for the Bayesian Skyline Plots were all below 5% value indicating their low 
false-positive rate. 
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Whole‐genome mutational analysis 
The total amount of mutations in relation with the length of the protein (Figure 6b) showed 
that HA, NA and PB2 have highest mutation rate over the period of 2009-2013. However 
when compared to the length of the protein, HA and NA have mutated more than PB2. The 
comparison graph shows also that PB1 segment is mutated the least, as assumed by the 
distance of the regression line. In total 18 590 nucleotide polymorphisms and 4657 amino acid 
substitutions were identified compared with the reference strain A/California/7/2009 in 135 
patient isolates. Eight virus isolates originated from four patients (two samplings per patient), 
differing in amino acid sequence and thereby indicating fast mutation rate. 
When comparing polymorphisms occurring in 2009-2013 (Figure 6c) it seems that HA has 
accumulated more amino acid substitutions than other proteins followed by M1 (involved in 
replication of the virus), NA (functioning at production of infectious virions) and PB2 (viral 
polymerase activity).  
The analysis of the 10 seasonal samples (subtype H3N2) revealed in total 1024 nucleotide 
and 238 amino acid substitutions when compared to the reference strain (A/Sydney/5/1997). 
Majority of the polymorphisms was detected in protein encoding sequences and especially in 
the neuraminidase gene. Interestingly 50% of seasonal sequences had a mutation in PB2 
protein (E627K)  that has been related to high virulence of avian influenza viruses (Tian, Qi 
et al. 2012).  
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Figure 6: Mutation analysis for the cumulative values. Chart 6a shows the total number of amino acid substitutions in 
each protein sequence (n=135). Chart 6b reveals the correlation between the length of the protein and the number of 
mutation. Chart 6c shows the polymorphisms accumulated from 2009‐2013. Abbreviations: HA – hemagglutinin, M1 – 
matrix protein 1, NA – neuraminidase, NP – nucleocapsid protein, NS2 – non‐structural protein 2, PA/PA‐X – polymerase 
activity proteins, PB1/PB2 – polymerase binding proteins. 
 
A manuscript was submitted to a journal called “Genome Announcements” about the 
evolutionary phylogenetic and mutational analysis of pandemic A(H1N1)pdm09 Finnish 
patient isolates.  
 
Structural analysis 
Mutations that could lead to more severe disease outcome often change the structure and 
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function of the specific protein. Severe clinical outcome of influenza infection is connected 
with mutations in the different binding sites of the proteins to either cell receptors or antiviral 
drugs (Pan, Cheung et al. 2010). 
Polymorphisms in hemagglutinin accumulate at the antigenic site of the protein affecting 
host immune response and resulting enhanced viral influenza replication. Several amino acid 
changes in HA were identified (Figure 7a,b) and localized on the protein structure to the sites 
potentially correlating to the severity of the disease (Pan, Cheung et al. 2010, Glinsky 2010).  
Also on neuraminidase several amino acid changes occurred, while interestingly on mutation 
identified in this study could cause oseltamivir resistance due to its close proximity to 
H275Y mutation (Figure 7c) (Pan, Cheung et al. 2010). The polymorphisms in polymerase 
subunit (PB2) located on structure on active sites (Figure 7d) and could affect the cap-
binding activity during virus replication inside the host cell. 
Figure 7: Mutations mapped in protein structures obtained from Protein Databank using PyMol software. a) and b) show 
polymorphisms mapped in the structure of hemagglutinin (HA) protein. c) shows the structure of neuraminidase and d) 
has polymerase protein (PB2). Arrows indicate the location of the amino acid substitutions that could correlate with the 
severity of the disease in the 3D structure of the protein. Orange spheres show other identified amino acid 
polymorphisms. 
 
Antiviral resistance 
Analysis of the amino acid alignment revealed that amantadine resistance S31N was found in 
all samples. Resistance markers for remantadine or zanamivir were not detected. However one 
isolate (A/Helsinki/598/2013) contained an amino acid substitution (E119K) that has been 
shown to cause oseltamivir resistance in N2 subtypes (Figure 8a). This is the first such amino acid 
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change observed in N1 subtype and also first reported potentially double resistant strain 
(amantadine and oseltamivir) in Finland. THL verified the presence of this mutation with 
Sanger sequencing. They identified very small amount of the polymorphisms in the original 
NPA sample (close to background noise), however the mutation was present in the majority 
of sequences obtained from the propagated (4th passage) isolate which was also used in the 
library preparation for Illumina sequencing. 
The change in the reading frame of the neuraminidase gene segment resulted from guanosine change 
to adenosine leading to the amino acid change from glytamic acid (E) to lysine (K) (Figure 8a). 
Plaque assay of sample 598 from 4th passage of in vitro propagated viruses revealed the 
mixture of different viruses which can be identified by the different size of spots (Figure 8b).  
Structural prediction with PyMol shows that polymorphism 119 E/K alters the properties of 
the binding pocket and could result in ineffective binding of oseltamivir (Figure 8c). 
The European Center of Disease Prevention and Control (ECDC) has been informed of this 
finding.  
.  
 
Figure 8: First potentially oseltamivir resistant A(H1N1)pdm09 strain identified in Finland. 8a) alignment of nucleotide 
sequences, change in the nucleotide sequence resulting in the amino acid shift EK marked in a red box. 8b) shows the 
plaque assay with different titres of the virus.  8c) amino acid change affecting oseltamivir (structure in green) binding 
properties visualized with PyMol software.  
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Discussion  
 
Sequencing methods in virological research 
 
Molecular virology techniques for genomic analysis and the creation of recombinant viruses 
are important in understanding of influenza viruses. In order to amplify the viral genes or 
segments for further studies, viral RNA is converted to double-stranded DNA from negative-
sense RNA using reverse transcription (RT) and PCR. The resulting amplicons can be probed, 
sequenced, or cloned into a variety of vectors for further analysis and for creating 
recombinant influenza A viruses by plasmid-based reverse genetics (Zhou, Wentworth 2012). 
 
Up to this date many varieties of RT-PCR have been developed taking into consideration 
further testing of the amplicons. However, the major obstacle with this method has been that 
equal amplification of all the 8 viral segments is not often achieved. Equal amplification is 
extremely important for proper whole-genome sequencing. Of the available methods, multi-
segment RT-PCR is useful because it doesn’t require in vitro propagation of viruses to 
increase the titer of the virus and is mainly used on diagnostic microarray studies (Zhou, 
Donnelly et al. 2009). When comparing two-step and one-step RT-PCR methods, one-step 
RT-PCR was found to be undoubtedly faster, cheaper and more efficient than two-step RT-
PCR method. However, in order to achieve strong amplification of all eight segments, viruses from 
NPAs were first propagated in vitro in MDCK cells. 
 
Since the development of sequencing methods that enable fast and large data sets to be 
processed, viral populations can also be analysed in unprecedented resolution. Massively 
parallel next generation sequencing provides such output. Illumina platform is leader in the 
sequencing market providing the cheapest, most time-efficient and easy to use service. The average 
run time is 11,5 days with the highest read length compared to other sequencing-platforms, 600GB. 
The negative side of this method is that it produces some sequence-related errors which 
increases the risk of missing important polymorphisms (Gullapalli, Desai et al. 2012, Watson, 
Welkers et al. 2013). 
In this thesis work 160 patient nasopharyngeal isolates were grown and amplified with 
optimized one-step RT-PCR method for full-genome sequencing. In total 135 sequences 
(including the 6 previous samples) were used in bioinformatical analysis. This study 
validated an efficient one-step RT-PCR method in the pipeline of sequencing of large data 
(total runtime was 14 days). 
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Evolutionary changes of influenza virus in Finland 
 
First whole-genome sequences of influenza A(H1N1)pdm09 were submitted to GenBank in 
2012 by Medical systems virology research group lead by Dr. Denis Kainov at FIMM, 
University of Helsinki, Finland. Analysis of 6 sequenced genomes originating from severe 
cases revealed C-terminal truncation of NS1 protein in one of the sequences 
(A/Helsinki/P14/2009). Other significant polymorphisms were not identified. The purpose of 
the work in this thesis was to analyse full-length sequences from substantial amount of 
influenza A(H1N1)pdm09 isolates collected since the pandemic year 2009 and perform 
extensive evolutionary and mutational analyses on the data set obtained.  
 
Bayesian modeling in virological research 
Bayesian interference analysis with interpreting mechanisms using MCMC simulation 
algoritms is widely used method in viral phylodynamic analysis. Advantages of this method 
include: 
• Combining past information to form a prior distribution for future analysis  
• Small and large sample cohorts is processed similarly 
• It follows the likelihood principle 
• It enables the identification of statistical parameters such as distribution in 95% 
credible intervals  
Disadvantages include: 
o It requires skills to mathematically formulate the correct prior 
o Posterior distributions are heavily influenced by the priors 
o High computational cost  
Markov Chain Monte Carlo provides the algoritms for  sampling the posterior distributions 
and visualizing the results (SAS Institute Inc 2009).  
 
Bayesian modeling on influenza A virus isolates obtained from Finnish patients 
Phylogenetic analysis and Bayesian Skyline plots of 135 virus isolates showed that amino acid 
changes in viral proteins have stronger effect on the mutation rate of the virus than nucleotide 
polymorphisms in the corresponding genes. Regardless of high standard deviation and low 
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ESS (that is in correlation with standard deviation), the obvious trend is that the biggest 
change in the virus occurred sometime in 2010/2011. When viral proteins were analysed 
separately, neuraminidase and hemagglutinin had been mutating more than others. This could 
affect the virulence of H1N1 due to polymorphisms on antigenic sites of these proteins and 
their role in evading immune responses during the infection. Interestingly, NA had started 
evolving sooner than HA. This tendency could have been affected by the vaccinations which 
are targeting neuraminidase rather than hemagglutinin protein. As described by Strengell et al., 
two vaccinations were offered to Finnish healthcare professionals against influenza 
A(H1N1)pdm09 virus: monovalent AS03-adjuvant pandemic influenza vaccine (marketing 
name Pandemrix™) in October 2009 and non-adjuvant trivalent seasonal influenza vaccine 
(marketing name Fluarix™) in 2010. Both of the vaccines contained influenza subtype from 
severe case, A/California/7/2009 (Strengell, Ikonen et al. 2012). However when influenza virus 
A(H1N1)pdm09 mutation rate changes were compared to the national vaccination timings in 
Finland, it became apparent that there is no significant connection between increase in virus 
mutation rate and vaccinations. 
Even though so far the studies on accumulating amino acid changes of A(H1N1)pdm09 
strain have not caused antigenic distinction from the type A influenza strain used in the 
vaccine strain (A/California/7/2009) produced in 2009-2012  the differences in evolving 
influenza isolates compared to the vaccine isolate could be significant enough to change the 
antigenicity of the circulating influenza isolates (Anton, Pozo et al. 2012). As Guarnaccia et 
al. experimentally demonstrated, the fast antigenic drift occurred in virus to escape from a 
low level vaccine response thus in response to increasing infection-induced immunity and 
vaccinations antigenic drift is more likely to occur, pushing circulating strain to change even 
more (Guarnaccia, Carolan et al. 2013).  
The results presented in this Master’s thesis suggests that the high substitution rate in protein 
sequences of circulating A(H1N1)pdm09 strain indicates the need for a new influenza A 
strain to be included in the upcoming vaccine. 
 
 
Viral polymorphisms affecting clinical outcome 
  
Many studies have identified possible mutations that could correlate with the severity of the 
disease. The most studied is the D222 polymorphism (numbering without the signal peptide) 
where substitutions from aspartic acid to glycine or to asparagine have been suggested to 
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lead to severe pathological outcome (Drews, Pabbaraju et al. 2011). In this thesis study no 
D222 substitutions were identified but polymorphisms in the close proximity sites were 
found (220S/T, 224S/N, 226K/E).  
Polymorphisms found to be present in 2013 but not in 2009 seem to not have significant 
effect on the virulence of A(H1N1)pdm09. However, abundant amount of distinct mutations 
were discovered which could relate to the severity of disease. Polymorphisms in the polymerase 
subunits have shown to increase the pandemic potential of an influenza virus. Notably large amount 
of mutations (in total 1671 on 135 patient isolates) in the polymerase subunits identified in this thesis 
study indicates A(H1N1)pm09 virus potentiality to escape from host barriers (Manz, Schwemmle et 
al. 2013). In addition, first reported double-resistant (oseltamivir and amantadine) strain is an 
alarming indication of changes occurring in the circulating A(H1N1)pdm09 that could have 
severe implication on general health of the Finnish population during the forthcoming 
epidemics.  
 
Analysing only the virus genetics does not give complete overview on the effects of viral 
mutations on the health of individuals. Host genomics and underlying conditions contribute 
to the outcome of the disease and should be taken into consideration. In order to draw 
comprehensive conclusions, further studies on host immune responses to different virus isolates, 
in different genetic background, should be performed and combined with the medical data. 
 
The role of E119 polymorphisms in NA in decreasing the susceptibility to antiviral drugs is 
showed by the study of Pan et al (Pan, Li et al. 2013).  
 
Conclusions and future prospects 
One-Step RT-PCR was shown to be the most effective way to equally amplify all 8 influenza 
H1N1 vRNA segments. The most rapid method for sequencing and analyzing large data set is 
next-generation sequencing. Influenza A(H1N1)pdm09 strain has evolved since 2009, with 
the most dramatic change occurring 2010/2011, possibly explaining re-emergence of this 
virus to the population on influenza season 2012/2013. Extensive polymorphisms were 
detected in virus isolates, especially in HA and NA proteins. The biological importance of 
amino acid substitutions needs to be assessed with functional studies. 
To improve the statistical parameters (decrease in standard deviation and increase posterior 
densities) in evolutionary modeling of influenza viruses more dynamic data set is required. 
Obtaining more severe (hospitalized patients in the ICU unit) and mild cases (home treated) 
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from the years 2009, 2010, 2011 and 2012 would improve statistical significance and reduce 
the level of type I error (alpha).   
In order to fully understand why some viruses affect one individual more than the other, host 
genomics and immunology need to be studied in parallel with virus genomics. 
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Supplementary data  
 
All the mutations located in mild and severe cases in reference to GenBank strain 
(A/California/7/2009) in appendix 1 and Bayesian Skyline Plots and phylogenetic trees of 
concatenated nucleotide and protein sequences as well as hemagglutinin and neuraminidase 
protein sequences in appendix 2a-2d. 
 
